Overexpression of transforming growth factor‐β3 immunohistochemical staining in extramammary Paget's disease, but downregulated expression in Bowen's disease

International Journal of Dermatology - Tập 40 Số 4 - Trang 262-267 - 2001
Tamihiro Kawakami1, Yoshinao Soma1, M. Mizoguchi1, Ryuzo Saito2
1From the Department of Dermatology, St. Marianna University School of Medicine, Kanagawa and
2Second Department of Dermatology, Toho University School of Medicine, Tokyo, Japan

Tóm tắt

AbstractBackground  The role of transforming growth factor‐β (TGF‐β) in carcinogenesis is complex, with some reports indicating a tumor inhibition role and others indicating a tumor promotion role. In particular, TGF‐β3 is thought to play a key role in controlling epithelial homeostasis. Immunopositive p53 has been demonstrated in a variety of human malignant tumors and its role in oncogenesis and tumor progression is thought to be important. Extramammary Paget's disease (EPD) and Bowen's disease are skin cancers of unknown histogenesis.Objective  To clarify the role of TGF‐β3 and p53 in EPD and Bowen's disease and to better understand the origin of these disorders.Methods  Specimens were obtained from 12 patients with EPD and 12 patients with Bowen's disease seen at our clinic between 1993 and 2000. TGF‐β3 and p53 immunohistochemical staining was performed.Results  In three of the 12 EPD patients and five of the 12 Bowen's disease patients, positive p53 staining was detected. In contrast, TGF‐β3 overexpression was detected in all EPD patients, whereas downregulated TGF‐β3 expression was detected in all Bowen's disease patients.Conclusions  The present data suggest different roles for TGF‐β3 in abnormal epidermal cells in EPD and Bowen's disease. Thus, TGF‐β3 expression may be modulated differently via a p53‐dependent or ‐independent pathway in the pathogenesis of EPD and Bowen's disease. Moreover, high TGF‐β expression appears to be a useful indicator of tumor activity in EPD.

Từ khóa


Tài liệu tham khảo

10.1016/0738-081X(93)90101-H

10.1097/00000372-199604000-00003

Kohler S, 1998, The differential diagnosis of Pagetoid cells in the epidermis, Mod Pathol, 11, 79

10.1016/S1085-5629(96)80020-4

10.1097/00004347-198403010-00004

10.1046/j.1365-2133.1996.138873.x

10.1046/j.1365-4362.1997.00044.x

10.1001/archderm.1996.03890280091013

10.1007/s004030050282

10.1007/978-3-642-80481-6_10

10.1002/path.1711710307

10.1210/mend-3-12-1977

McNutt NS, 1994, Abnormalities of p53 protein expression in cutaneous disorders, Arch Dermatol, 130, 225, 10.1001/archderm.1994.01690020091015

10.1046/j.1523-1747.1998.00090.x

10.1016/0092-8674(92)90421-8

10.1111/j.1365-2133.1992.tb14866.x

10.1046/j.1365-2133.1996.d01-1068.x

10.1046/j.1523-1747.1998.00167.x

10.1097/00005537-199607000-00020

10.1016/S0022-2143(96)80006-0

10.1111/1523-1747.ep12363594

10.1046/j.1365-2133.1996.d01-899.x

El‐Deiry WS, 1995, Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues, Cancer Res, 55, 2910

10.1159/000245947

Wikonkal NM, 1997, bcl‐2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers, Arch Dermatol, 133, 599, 10.1001/archderm.1997.03890410055007

10.1111/1523-1747.ep12475717

Perez MI, 1997, p53 oncoprotein expression and gene mutations in some keratoacanthomas, Arch Dermatol, 133, 189, 10.1001/archderm.1997.03890380061009

Rehman I, 1996, Genetic change in actinic keratoses, Oncogene, 12, 2483

Puig L, 1995, Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration, Arch Dermatol, 131, 353, 10.1001/archderm.1995.01690150119025

10.1111/j.1365-2133.1997.tb03686.x

10.1093/ajcp/110.1.16

10.1023/a:1005865812918

10.1002/jcp.1041550127

10.1101/gad.8.2.133

10.1038/sj.onc.1202161

Cui W, 1994, Lack of transforming growth factor‐β1 expression in benign skin tumors of p53 null mice is prognostic for a high risk of malignant conversion, Cancer Res, 54, 5831

10.1101/gad.8.20.2429

10.1073/pnas.88.21.9613